All lobbying filings

Arentfox Schiff LLP

Arentfox Schiff LLP filed a Q4 report for Organogenesis Inc. on January 20, 2026, reporting $70,000 in lobbying income.

Lobbying for Organogenesis Inc. · Biotech company

As filed: ARENTFOX SCHIFF LLP for ORGANOGENESIS INC.

All filings by Arentfox Schiff LLP · Everything Organogenesis Inc. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$70,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products (CY2026) Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 5304 and S. 2587 (Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, 2026), regarding reimbursement for chronic wound healing products

Health Issues

Food and Drug Administration policy on chronic wound healing products

Bills named in this filing 4

H.R. 5768
Skin Substitute Access and Payment Reform Act
S. 2561
Skin Substitute Access and Payment Reform Act of 2025
H.R. 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S. 2587
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.